Trisomy 8 in Philadelphia-negative cells during imatinib therapy

4Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Targeted therapy with imatinib selectively suppresses Philadelphia-positive cells in chronic myeloid leukemia cells, with reappearance of apparently normal hemopoiesis in a considerable number of patients. Recently, clonal abnormalities have been observed in Philadelphia-negative cells during imatinib therapy, the biologic and prognostic significance of which is actually unknown. A case of trisomy 8 occurring in Philadelphia-negative cells, which was treated by bone marrow transplantation, is reported. Chromosomal abnormalities in Philadelphia-negative cells do not seem to herald disease transformation, but the long-term prognosis may be influenced by an increased incidence of myelodysplasia in younger patients. © 2004 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Bernardeschi, P., Fiorentini, G., Rossi, S., Dentico, P., Simi, P., & Guidi, S. (2004). Trisomy 8 in Philadelphia-negative cells during imatinib therapy. American Journal of Hematology, 77(1), 88–89. https://doi.org/10.1002/ajh.20133

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free